Clinical Trials · NCT06962280
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 465
- Start date
- May 2025
- Locations
- 79 sites, 10 countries
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c)